Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

Genomic instability and mutations underlie the hallmarks of cancer—genetic alterations
determine cancer cell fate by affecting cell proliferation, apoptosis and immune response …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

For cancer screening to be successful, it should primarily detect cancers with lethal potential
or their precursors early, leading to therapy that reduces mortality and morbidity. Screening …

Annotation of prostate cancer genomes provides a foundation for discoveries that can
impact disease understanding and treatment. Concordant assessment of DNA copy number …

Prostate cancers remain indolent in the majority of individuals but behave aggressively in a
minority,. The molecular basis for this clinical heterogeneity remains incompletely …

Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …

The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to
develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on …

Chromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the
oncogenic ETS transcription factor ERG occur in approximately 50% of prostate cancers, but …

Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for men …